Qian et al. Journal of Experimental & Clinical Cancer Research 2010, 29:111 http://www.jeccr.com/content/29/1/111 Page 5 of 5 Author details 1Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu 212002, China. 2Department of Hematology, The First Hospital of Nanjing Medical University, Jiangsu Provincial People’s Hospital, Nanjing, Jiangsu, 210029, China. Authors’ contributions QJ and LJY designed the study, analyzed the data and wrote the manuscript; QZ, LJ, YDM and CQ performed all experiments; JRB, LY and XGF gave assistance with technical performance and contributed to the writing of the manuscript. All authors read and approved the final manuscript. Competing interests The authors declare that they have no competing interests. Received: 19 July 2010 Accepted: 12 August 2010 Published: 12 August 2010 References 1. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD: FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000, 2:249-256. 2. Zhao J, Guan JL: Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 2009, 28:35-49. 3. Recher C, Ysebaert L, Beyne-Rauzy O, Mansat-De Mas V, Ruidavets JB, Cariven P, Demur C, Payrastre B, Laurent G, Racaud-Sultan C: Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res 2004, 64:3191-3197. 4. Tavernier-Tardy E, Cornillon J, Campos L, Flandrin P, Duval A, Nadal N, Guyotat D: Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk Res 2009, 33:764-768. 5. Le Y, Xu L, Lu J, Fang J, Nardi V, Chai L, Silberstein LE: FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells. Am J Hematol 2009, 84:273-278. 6. Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, O’Hare T, Heinrich MC, Deininger MW, Druker BJ: RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 2008, 111:2238-2245. 7. Hildebrand JD, Taylor JM, Parsons JT: An SH3 domain-containing GTPase- activating protein for Rho and Cdc42 associates with focal adhesion kinase. Mol Cell Biol 1996, 6:3169-3178. 8. Sahai E, Olson MF, Marshall CJ: Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J 2001, 20:755-766. 9. Borkhardt A, Bojesen S, Haas OA, Fuchs U, Bartelheimer D, Loncarevic IF, Bohle RM, Harbott J, Repp R, Jaeger U, Viehmann S, Henn T, Korth P, Scharr D, Lampert F: The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci USA 2000, 97:9168-9173. 10. Bojesen SE, Ammerpohl O, Weinhäusl A, Haas OA, Mettal H, Bohle RM, Borkhardt A, Fuchs U: Characterisation of the GRAF gene promoter and its methylation in patients with acute myeloid leukaemia and myelodysplastic syndrome. Br J Cancer 2006, 94:323-332. 11. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625. 12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199. 13. Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302. 14. Lo Coco F, Foa R: Diagnostic and prognostic advances in the immunophenotypic and genetic characterization of acute leukaemia. Eur J Haematol 1995, 55:1-9. 15. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/ Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083. 16. Qian J, Wang YL, Lin J, Yao DM, Xu WR, Wu CY: Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia. Eur J Haematol 2009, 82:119-123. 17. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088. 18. Karlsson R, Pedersen ED, Wang Z, Brakebusch C: Rho GTPase function in tumorigenesis. Biochim Biophys Acta 2009, 1796:91-98. 19. Benitah SA, Valerón PF, van Aelst L, Marshall CJ, Lacal JC: Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 2004, 1705:121-132. 20. Aznar S, Fernández-Valerón P, Espina C, Lacal JC: Rho GTPases: potential candidates for anticancer therapy. Cancer Lett 2004, 206:181-191. 21. Vidal A, Millard SS, Miller JP, Koff A: Rho activity can alter the translation of p27 mRNA and is important for RasV12-induced transformation in a manner dependent on p27 status. J Biol Chem 2002, 277:16433-16440. 22. Seasholtz TM, Zhang T, Morissette MR, Howes AL, Yang AH, Brown JH: Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats. Circ Res 2001, 89:488-495. 23. Olson MF, Paterson HF, Marshall CJ: Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature 1998, 394:295-299. 24. Liberto M, Cobrinik D, Minden A: Rho regulates p21(CIP1), cyclin D1, and checkpoint control in mammary epithelial cells. Oncogene 2002, 21:1590-1599. 25. Vega FM, Ridley AJ: Rho GTPases in cancer cell biology. FEBS Lett 2008, 582:2093-2101. 26. Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7:441-453. 27. Calabretta B, Perrotti D: The biology of CML blast crisis. Blood 2004, 103:4010-4022. 28. Sahay S, Pannucci NL, Mahon GM, Rodriguez PL, Megjugorac NJ, Kostenko EV, Ozer HL, Whitehead IP: The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. Oncogene 2008, 27:2064-2071. doi:10.1186/1756-9966-29-111 Cite this article as: Qian et al.: GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies. Journal of Experimental & Clinical Cancer Research 2010 29:111. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit